GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LadRx Corp (OTCPK:LADX) » Definitions » ROE %

LadRx (LADX) ROE %

: -640.30% (As of Dec. 2023)
View and export this data going back to 1986. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. LadRx's annualized net income for the quarter that ended in Dec. 2023 was $-3.43 Mil. LadRx's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $0.54 Mil. Therefore, LadRx's annualized ROE % for the quarter that ended in Dec. 2023 was -640.30%.

The historical rank and industry rank for LadRx's ROE % or its related term are showing as below:

LADX' s ROE % Range Over the Past 10 Years
Min: -193.11   Med: -90.65   Max: 601.5
Current: 113.86

During the past 13 years, LadRx's highest ROE % was 601.50%. The lowest was -193.11%. And the median was -90.65%.

LADX's ROE % is ranked better than
98.82% of 1360 companies
in the Biotechnology industry
Industry Median: -44.08 vs LADX: 113.86

LadRx ROE % Historical Data

The historical data trend for LadRx's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LadRx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -40.28 -55.67 -193.11 -174.97 601.50

LadRx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -711.11 - 3,799.70 -237.73 -640.30

Competitive Comparison

For the Biotechnology subindustry, LadRx's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LadRx ROE % Distribution

For the Biotechnology industry and Healthcare sector, LadRx's ROE % distribution charts can be found below:

* The bar in red indicates where LadRx's ROE % falls into.



LadRx ROE % Calculation

LadRx's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=0.4/( (0.026+0.107)/ 2 )
=0.4/0.0665
=601.50 %

LadRx's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-3.432/( (0.965+0.107)/ 2 )
=-3.432/0.536
=-640.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


LadRx  (OTCPK:LADX) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-3.432/0.536
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-3.432 / 0)*(0 / 2.687)*(2.687 / 0.536)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*5.0131
=ROA %*Equity Multiplier
=N/A %*5.0131
=-640.30 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-3.432/0.536
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-3.432 / -3.432) * (-3.432 / -3.528) * (-3.528 / 0) * (0 / 2.687) * (2.687 / 0.536)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.9728 * N/A % * 0 * 5.0131
=-640.30 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


LadRx ROE % Related Terms

Thank you for viewing the detailed overview of LadRx's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


LadRx (LADX) Business Description

Traded in Other Exchanges
N/A
Address
11726 San Vicente Boulevard, Suite 650, Los Angeles, CA, USA, 90049
LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.
Executives
Cary J Claiborne director 3056 SENECA CHIEF TRAIL, ELLICOTT CITY MD 21042
Stephen Snowdy officer: Chief Executive Officer C/O CYTRX CORPORATION, 11726 SAN VICENTE BOULEVARD, SUITE 650, LOS ANGELES CA 90049
Jennifer K. Simpson director C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019
Eric Curtis officer: Pres., Chief Operating Officer ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Felix Kratz officer: Vice President Drug Discovery 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Joel K Caldwell director 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Chawla Shanta M.d. officer: Senior VP-Drug Development 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Earl W Brien director 11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Olivia C Ware officer: Chief Commercial Officer 11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Cheryl Cohen director C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Eric Jay Selter director 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Anita J Chawla director 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Joseph Rubinfeld director C/O SUPERGEN INC, 4140 DUBLIN BLVD STE 200, DUBLIN CA 94568
Douglas Scott Wieland officer: Sr VP - Drug Development 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Louis Ignarro director 11726 SAN VICENTE BLVD, STE 650, LOS ANGELES CA 90049

LadRx (LADX) Headlines

From GuruFocus

CytRx Corporation Reports Third Quarter 2018 Financial Results

By PRNewswire PRNewswire 11-02-2018

CytRx Corporation to Commence Trading on OTCQB Venture Market

By PRNewswire PRNewswire 05-31-2019

CytRx Corporation to Present at the 2018 MicroCap Conference

By PRNewswire PRNewswire 09-25-2018